A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.

US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.

Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.

A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.